GlassScriptPhysician profile
Jeffrey Dysart
NPI 1154361558
$16,504.46
in general payments reported to CMS, 2019-2025
73 companies · $1,949 in 2025
The $1,949 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,341 · 2020: $2,339 · 2021: $2,466 · 2022: $4,208 · 2023: $1,300 · 2024: $1,900 · 2025: $1,949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,149.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,974.80 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals LP | $1,801.13 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $1,246.12 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $1,176.21 | 2019-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $912.20 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $714.96 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $572.19 | 2019-2025 | |
| Gilead Sciences, INC. | $430.04 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $364.45 | 2019-2025 | |
| Allergan, INC. | $317.78 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $249.60 | 2019-2024 | Ingrezza |
| Merck Sharp & Dohme LLC | $248.95 | 2019-2022 | |
| Boston Scientific Corporation | $237.52 | 2019-2024 | Watchman Access System |
| Biohaven Pharmaceuticals, INC. | $224.34 | 2020-2021 | |
| Antares Pharma, INC. | $214.53 | 2019-2024 | Xyosted, Nocdurna, Tlando |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Dysart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.